Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters

Tuberculosis

Volumn 96, Issue , 2016, Pages 150-157

  Te Brake, Lindsey H M ^a,b   Russel, Frans G M ^a   Van Den Heuvel, Jeroen J M W ^a   De Knegt, Gerjo J ^c   De Steenwinkel, Jurriaan E ^c   Burger, David M ^b   Aarnoutse, Rob E ^b   Koenderink, Jan B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ABC transporters; Drug drug interactions; Membrane vesicles; Protein overexpression; Tuberculosis; Vesicular transport assay

Indexed keywords

ABC TRANSPORTER; AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIMYCOBACTERIAL AGENT; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; THIOACETAZONE; THIORIDAZINE; TIMCODAR; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VERAPAMIL; ABCB1 PROTEIN, HUMAN; ABCB11 PROTEIN, HUMAN; ABCG2 PROTEIN, HUMAN; BREAST CANCER RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; TUMOR PROTEIN;

ARTICLE; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SCREENING; DRUG TRANSPORT; EMBRYO; GENE OVEREXPRESSION; HEK293 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INHIBITION KINETICS; MEMBRANE VESICLE; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CELL MEMBRANE; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; GENETIC TRANSFECTION; GENETICS; METABOLISM;

ANTITUBERCULAR AGENTS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 2; ATP-BINDING CASSETTE TRANSPORTERS; CELL MEMBRANE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HEK293 CELLS; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEINS; TRANSFECTION;

EID: 84954407685     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2015.08.004     Document Type: Article

References (41)

1. WHO Global tuberculosis report 2014 2014 World Health Organization
2. WHO Treatment of tuberculosis: guidelines for national programmes 4th ed. 2009 Available at: http://www.who.int/tb/publications/tb-treatmentguidelines/en/
3. A.I. Zumla, S.H. Gillespie, M. Hoelscher, P.P. Philips, S.T. Cole, I. Abubakar, T.D. McHugh, M. Schito, M. Maeurer, and A.J. Nunn New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects Lancet Infect Dis 14 2014 327 340 10.1016/S1473-3099(13)70328-1
4. A. Van Deun, A.K. Maug, M.A. Salim, P.K. Das, M.R. Sarker, P. Daru, and H.L. Rieder Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis Am J Respir Crit Care Med 182 2010 684 692 10.1164/rccm.201001-0077OC
5. C.Y. Jeon, and M.B. Murray Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies PLoS Med 5 2008 e152 10.1371/journal.pmed.0050152
6. H.H. Semvua, G.S. Kibiki, E.R. Kisanga, M.J. Boeree, D.M. Burger, and R. Aarnoutse Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings Ther Drug Monit 37 2015 22 32 10.1097/FTD.0000000000000108
7. S. Choudhuri, and C.D. Klaassen Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters Int J Toxicol 25 2006 231 259 10.1080/10915810600746023
8. C.J. Endres, P. Hsiao, F.S. Chung, and J.D. Unadkat The role of transporters in drug interactions Eur J Pharm Sci off J Eur Fed Pharm Sci 27 2006 501 517 10.1016/j.ejps.2005.11.002
9. H.K. Han Role of transporters in drug interactions Archives Pharmacal Res 34 2011 1865 1877 10.1007/s12272-011-1107-y
10. J. Rengelshausen, C. Goggelmann, J. Burhenne, K.D. Riedel, J. Ludwig, J. Weiss, G. Mikus, I. Walter-Sack, and W.E. Haefeli Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction Br J Clin Pharmacol 56 2003 32 38
11. J. Hughes, and A. Crowe Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics J Pharmacol Sci 113 2010 315 324
12. H. Xu, and A. Rashkow Clarithromycin-induced digoxin toxicity: a case report and a review of the literature Conn Med 65 2001 527 529
13. K.M. Giacomini, S.M. Huang, D.J. Tweedie, L.Z. Benet, K.L. Brouwer, X. Chu, A. Dahlin, R. Evers, V. Fischer, K.M. Hillgren, K.A. Hoffmaster, T. Ishikawa, D. Keppler, R.B. Kim, C.A. Lee, M. Niemi, J.W. Polli, Y. Sugiyama, P.W. Swaan, J.A. Ware, S.H. Wright, S.W. Yee, M.J. Zamek-Gliszczynski, and L. Zhang International Transporter Consortium: Membrane transporters in drug development Nat Rev Drug Discov 9 2010 215 236 10.1038/nrd3028
14. B. Marquez Bacterial efflux systems and efflux pumps inhibitors Biochimie 87 2005 1137 1147 10.1016/j.biochi.2005.04.012
15. A.J. Phipps Personal communication 2015 Sequella Inc
16. L. Rodrigues, D. Wagner, M. Viveiros, D. Sampaio, I. Couto, M. Vavra, W.V. Kern, and L. Amaral Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis J Antimicrob Chemother 61 2008 1076 1082 10.1093/jac/dkn070
17. K.N. Adams, J.D. Szumowski, and L. Ramakrishnan Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs J Infect Dis 210 2014 456 466 10.1093/infdis/jiu095
18. T.H. Grossman, C.M. Shoen, S.M. Jones, P.L. Jones, M.H. Cynamon, and C.P. Locher The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents Antimicrob Agents Chemother 59 2015 1534 1541 10.1128/aac.04271-14
19. T.H. Grossman, C.M. Shoen, S.M. Jones, P.L. Jones, M.H. Cynamon, and C.P. Locher The efflux pump inhibitor timcodar (VX-853) Improves the potency of anti-Mycobacterial agents Antimicrob Agents Chemother 59 3 2015 Mar 1534 1541 10.1128/AAC.04271-14 Epub 2014 Dec 22
20. K.A. Sacksteder, M. Protopopova, C.E. Barry 3rd, K. Andries, and C.A. Nacy Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action Future Microbiol 7 2012 823 837 10.2217/fmb.12.56
21. A.A. El-Sheikh, J.J. van den Heuvel, E. Krieger, F.G. Russel, and J.B. Koenderink Functional role of arginine 375 in transmembrane helix 6 of multidrug resistance protein 4 (MRP4/ABCC4) Mol Pharmacol 74 2008 964 971 10.1124/mol.107.043661
22. M.L. Reitman, X. Chu, X. Cai, J. Yabut, R. Venkatasubramanian, S. Zajic, J.A. Stone, Y. Ding, R. Witter, C. Gibson, K. Roupe, R. Evers, J.A. Wagner, and A. Stoch Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design Clin Pharmacol Ther 89 2011 234 242 10.1038/clpt.2010.271
23. B.J. Kirby, A.C. Collier, E.D. Kharasch, D. Whittington, K.E. Thummel, and J.D. Unadkat Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion Drug Metabol Dispos Biol Fate Chem 40 2012 610 616 10.1124/dmd.111.042705
24. S. Mita, H. Suzuki, H. Akita, H. Hayashi, R. Onuki, A.F. Hofmann, and Y. Sugiyama Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs Drug Metabol Dispos Biol Fate Chem 34 2006 1575 1581 10.1124/dmd.105.008748
25. T. Dey, G. Brigden, H. Cox, Z. Shubber, G. Cooke, and N. Ford Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis J Antimicrob Chemother 68 2013 284 293 10.1093/jac/dks389
26. N. Padayatchi, M. Gopal, R. Naidoo, L. Werner, K. Naidoo, I. Master, and M.R. O'Donnell Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study J Antimicrob Chemother 69 11 2014 Nov 3103 3107 10.1093/jac/dku235 Epub 2014 Jun 30
27. J.H. Grosset, S. Tyagi, D.V. Almeida, P.J. Converse, S.Y. Li, N.C. Ammerman, W.R. Bishai, D. Enarson, and A. Trebucq Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice Am J Respir Crit Care Med 188 2013 608 612 10.1164/rccm.201304-0753OC
28. K. Williams, A. Minkowski, O. Amoabeng, C.A. Peloquin, D. Taylor, K. Andries, R.S. Wallis, K.E. Mdluli, and E.L. Nuermberger Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis Antimicrob Agents Chemother 56 2012 3114 3120 10.1128/AAC.00384-12
29. S. Tang, L. Yao, X. Hao, Y. Liu, L. Zeng, G. Liu, M. Li, F. Li, M. Wu, Y. Zhu, H. Sun, J. Gu, X. Wang, and Z. Zhang Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China Clin Infect Dis Off Publ Infect Dis Soc Am 60 2015 1361 1367 10.1093/cid/civ027
30. Y. Horita, and N. Doi Comparative study of the effects of antituberculosis drugs and antiretroviral drugs on cytochrome P450 3A4 and P-glycoprotein Antimicrob Agents Chemother 58 2014 3168 3176 10.1128/AAC.02278-13
31. M.C. Cholo, H.C. Steel, P.B. Fourie, W.A. Germishuizen, and R. Anderson Clofazimine: current status and future prospects J Antimicrob Chemother 67 2012 290 298 10.1093/jac/dkr444
32. L.A. Cone, D.R. Woodard, J.C. Simmons, and M.A. Sonnenshein Drug interactions in patients with AIDS Clin Infect Dis Off Publ Infect Dis Soc Am 15 1992 1066 1068
33. C. Luna-Tortos, M. Fedrowitz, and W. Loscher Several major antiepileptic drugs are substrates for human P-glycoprotein Neuropharmacology 55 2008 1364 1375 10.1016/j.neuropharm.2008.08.032
34. S. Alvariza, P. Fagiolino, M. Vazquez, A. Rosillo de la Torre, S. Orozco Suarez, and L. Rocha Verapamil effect on phenytoin pharmacokinetics in rats Epilepsy Res 107 2013 51 55 10.1016/j.eplepsyres.2013.09.001
35. S. Mullin, N. Mani, and T.H. Grossman Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853) Antimicrob Agents Chemother 48 2004 4171 4176 10.1128/AAC.48.11.4171-4176.2004
36. H.K. Thanacoody Thioridazine: resurrection as an antimicrobial agent? Br J Clin Pharmacol 64 2007 566 574 10.1111/j.1365-2125.2007.03021.x
37. D. Ordway, M. Viveiros, C. Leandro, R. Bettencourt, J. Almeida, M. Martins, J.E. Kristiansen, J. Molnar, and L. Amaral Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis Antimicrob Agents Chemother 47 2003 917 922
38. W.A. Daniel, M. Syrek, A. Mach, J. Wojcikowski, and J. Boksa Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment Pol J Pharmacol 49 1997 439 452
39. R.C. Hartkoorn, B. Chandler, A. Owen, S.A. Ward, S. Bertel Squire, D.J. Back, and S.H. Khoo Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein Tuberculosis 87 2007 248 255 10.1016/j.tube.2006.12.001
40. D.J. Begley Delivery of therapeutic agents to the central nervous system: the problems and the possibilities Pharmacol Ther 104 2004 29 45 10.1016/j.pharmthera.2004.08.001
41. C. Kohle, and K.W. Bock Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor Biochem Pharmacol 77 2009 689 699 10.1016/j.bcp.2008.05.020